Skip to main navigation Skip to search Skip to main content

MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

  • Maria Grazia Rodriquenz
  • , Giandomenico Roviello
  • , Alberto D'Angelo
  • , Daniele Lavacchi
  • , Franco Roviello
  • , Karol Polom
  • IRCCS CROB
  • University of Florence
  • Sasol Technology (UK) Ltd
  • Careggi University Hospital
  • Università degli Studi di Siena
  • Gdansk Medical University

Research output: Contribution to journalReview articlepeer-review

74   Link opens in a new tab Citations (SciVal)
66 Downloads (Pure)

Abstract

Gastric cancers have been historically classified based on histomorphologic features. The Cancer Genome Atlas network reported the comprehensive identification of genetic alterations associated with gastric cancer, identifying four distinct subtypes- Epstein-Barr virus (EBV)-positive, microsatellite-unstable/instability (MSI), genomically stable and chromosomal instability. In particular, EBV-positive and MSI gastric cancers seem responsive to novel immunotherapies drugs. The aim of this review is to describe MSI and EBV positive gastric cancer's subgroups and their relationship with novel immunotherapy.

Original languageEnglish
Article number1427
JournalJournal of Clinical Medicine
Volume9
Issue number5
DOIs
Publication statusPublished - 11 May 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy'. Together they form a unique fingerprint.

Cite this